Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban-or rivaroxaban-associated intracranial hemorrhages

H Pham, WG Medford, S Horst, M Levesque… - The American Journal of …, 2022 - Elsevier
Background Existing research recommends either andexanet alfa (AA) or four-factor
prothrombin complex concentrate (4F-PCC) as an antidote for major bleeding events due to …
被引用次数：25 相关文章

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban-or rivaroxaban-associated intracranial hemorrhages

H Pham, WG Medford, S Horst… - The American …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Existing research recommends either andexanet alfa (AA) or four-factor
prothrombin complex concentrate (4F-PCC) as an antidote for major bleeding events due to …
[PDF] researchgate.net

[PDF][PDF] Evaluation of andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban-or rivaroxaban-associated intracranial …

WG Medford, S Horst - American Journal of Emergency Medicine, 2022 - researchgate.net
Haithuy Pham, PharmD a,⁎, Whitney Gibson Medford, PharmD, BCCCP c, f, Spencer Horst,
PharmD, BCPS b, Melissa Levesque, PharmD, BCCCP c, David Ragoonanan, PharmD …

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban-or rivaroxaban-associated intracranial hemorrhages.

H Pham, WG Medford, S Horst, M Levesque… - The American Journal …, 2022 - europepmc.org
Background Existing research recommends either andexanet alfa (AA) or four-factor
prothrombin complex concentrate (4F-PCC) as an antidote for major bleeding events due to …
[PDF] researchgate.net

[PDF][PDF] Evaluation of andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban-or rivaroxaban-associated intracranial …

WG Medford, S Horst - American Journal of Emergency Medicine, 2022 - researchgate.net
Haithuy Pham, PharmD a,⁎, Whitney Gibson Medford, PharmD, BCCCP c, f, Spencer Horst,
PharmD, BCPS b, Melissa Levesque, PharmD, BCCCP c, David Ragoonanan, PharmD …